International Journal of Antimicrobial Agents
Volume 35, Issue 6 , Pages 603-605 , June 2010

Pharmacokinetics of garenoxacin in elderly patients with respiratory tract infections

  • Yoshinobu Ohsaki

      Affiliations

    • Respiratory Center, Asahikawa Medical College, 2-1-1-1 Midorigaoka Higashi, Asahikawa, Hokkaido 078-8510, Japan
    • Corresponding Author InformationCorresponding author. Tel.: +81 166 69 3290; fax: +81 166 69 3299.
    • ,
  • Kazutoyo Morita

      Affiliations

    • Shibetsu City Hospital, Shibetsu, Japan
    • ,
  • Hiroki Takeda

      Affiliations

    • Asahikawa Yoshida Hospital, Asahikawa, Japan
    • ,
  • Satoshi Kishino

      Affiliations

    • Department of Medication Use Analysis and Clinical Research, Meiji Pharmaceutical University, Tokyo, Japan
    • ,
  • Shunsuke Okumura

      Affiliations

    • Respiratory Center, Asahikawa Medical College, 2-1-1-1 Midorigaoka Higashi, Asahikawa, Hokkaido 078-8510, Japan
    • ,
  • Satoru Fujiuchi

      Affiliations

    • Department of Clinical Research, National Hospital Organization, Dohoku Hospital, Asahikawa, Japan

Received 22 December 2009 ,Accepted 12 January 2010.

References 

  1. File TM, Niederman MS. Antimicrobial therapy of community-acquired pneumonia. Infect Dis Clin North Am. 2004;18:993–1016
  2. Craig WA. Does the dose matter?. Clin Infect Dis. 2001;33(Suppl. 3):S233–S237
  3. Andes D, Craig WA. Pharmacodynamics of the new des-f(6)-quinolone garenoxacin in a murine thigh infection model. Antimicrob Agents Chemother. 2003;47:3935–3941
  4. Noreddin AM, Reese AA, Ostroski M, Hoban DJ, Zhanel GG. Comparative pharmacodynamics of garenoxacin, gemifloxacin, and moxifloxacin in community-acquired pneumonia caused by Streptococcus pneumoniae: a Monte Carlo simulation analysis. Clin Ther. 2007;29:2685–2689
  5. Takahata M, Shimakura M, Hori R, Kizawa K, Todo Y, Minami S, et al. In vitro and in vivo efficacies of T-3811ME (BMS-284756) against Mycoplasma pneumoniae. Antimicrob Agents Chemother. 2001;45:312–315
  6. Ameyama S, Shinmura Y, Takahata M. Inhibitory activities of quinolones against DNA gyrase of Chlamydia pneumoniae. Antimicrob Agents Chemother. 2003;47:2327–2329
  7. Takagi H, Tanaka K, Tsuda H, Kobayashi H. Clinical studies of garenoxacin. Int J Antimicrob Agents. 2008;32:468–474
  8. Uchida E. Phase 1 clinical studies of oral garenoxacin in healthy Japanese adult subjects. Jpn J Chemother. 2007;55(Suppl. 1):95–115
  9. Krishna G, Gajjar D, Swan S, Marbury T, Grasela DM, Wang Z. Garenoxacin pharmacokinetics in subjects with renal impairment. Curr Med Res Opin. 2007;23:649–657
  10. Hayakawa H, Fukushima Y, Kato H, Fukumoto H, Kadota T, Yamamoto H, et al. Metabolism and disposition of novel des-fluoro quinolone garenoxacin in experimental animals and an interspecies scaling of pharmacokinetic parameters. Drug Metab Dispos. 2003;31:1409–1418
  11. Kobayashi H, Tanigawara Y, Watanabe A, Aoki N, Sano Y, Odagiri S, et al. Phase III study of garenoxacin in patients with secondary infection of chronic respiratory diseases. Jpn J Chemother. 2007;55(Suppl. 1):144–161
  12. Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron. 1976;16:31–41
  13. Otani T, Tanaka M, Ito E, Kurosaka Y, Murakami Y, Onodera K, et al. In vitro and in vivo antibacterial activities of DK-507k, a novel fluoroquinolone. Antimicrob Agents Chemother. 2003;47:3750–3759
  14. Madaras-Kelly KJ, Demasters TA. In vitro characterization of fluoroquinolone concentration/MIC antimicrobial activity and resistance while simulating clinical pharmacokinetics of levofloxacin, ofloxacin, or ciprofloxacin against Streptococcus pneumoniae. Diagn Microbiol Infect Dis. 2000;37:253–260

PII: S0924-8579(10)00065-8

doi: 10.1016/j.ijantimicag.2010.01.020

International Journal of Antimicrobial Agents
Volume 35, Issue 6 , Pages 603-605 , June 2010

Article Tools

* Image Usage & Resolution